Description
Glibenclamide & Metformin Hydrochloride Tablets
Healthy Inc is a specialized global supplier and exporter of advanced endocrinology, metabolic health, and public health therapeutics. We provide ultra-high-purity, kinetically stable Glibenclamide and Metformin FDC Tablets, manufactured in WHO–GMP certified, high-precision anti-diabetic manufacturing facilities. This “Sulfonylurea & Biguanide Combination” is a massive-volume strategic export to National Diabetes Programs, retail pharmacy chains, and international B2B distributors, serving as the globally preferred intervention for patients whose blood glucose is not controlled by diet or monotherapy.
Product Overview
This formulation operates as a “Dual-Pathway Glycemic Regulator.” It ensures patient safety by targeting both insulin deficiency and insulin resistance simultaneously in a single, high-compliance dosage form.
Mechanism 1 (Insulin Secretagogue – Glibenclamide): Glibenclamide physically binds to ATP-sensitive potassium channels in the pancreatic beta cells. This chemically triggers the physical release of stored insulin into the bloodstream.
Mechanism 2 (Hepatic Glucose Inhibition – Metformin): Metformin physically activates AMPK. This chemically suppresses the liver’s physical production of glucose (Gluconeogenesis) and physically improves the chemical sensitivity of peripheral tissues to insulin.
Mechanism 3 (Fixed-Dose Synergy): By combining a secretagogue with a sensitizer, the treatment physically achieves Superior Glycemic Control with a lower risk of secondary treatment failure than monotherapy.
Product Composition & Standard Strengths
We supply this product in standardized Fixed-Dose Combinations (FDCs) designed for flexible clinical titration.
| Active Ingredient | Standard Strengths (per Tablet) | Primary Clinical Function |
| Metformin HCl | 400 mg / 500 mg | The Foundation: Reduces glucose production. |
| Glibenclamide (Glyburide) | 2.5 mg / 5 mg | The Stimulator: Enhances insulin secretion. |
| Excipients | Pharma Grade | The Matrix: Ensures stability of the FDC. |
Technical & Logistics Specifications
HS Code: 3004.90.99 (Medicaments acting on the metabolic system / Others)
CAS Numbers: 10238-21-8 (Glibenclamide) / 1115-70-4 (Metformin)
Dosage Form: Oral Tablet (Film-Coated or Uncoated)
Packaging: 10 or 14 Tablets per Blister in high-barrier Alu-Alu or PVC/PVDC. Our specialized packaging ensures 36-month stability in Zone IVb tropical climates.
Manufacturing Authority & Compliance
Dual-API Stability Management: Combining a Sulfonylurea and a Biguanide is physically complex. Our manufacturing process utilizes Advanced Dry-Granulation, physically ensuring that the two chemical agents do not interact or degrade within the tablet matrix—a critical factor for shelf-life in export markets.
Content Uniformity: We utilize Automated High-Speed Compression, physically ensuring that the micro-dose Glibenclamide (2.5mg/5mg) is chemically uniform across every single tablet in a high-volume batch.
Bioavailability Validation: We utilize Comparative Dissolution Profiling, physically ensuring our FDC is chemically bioequivalent to global innovator brands, meeting the stringent requirements of international B2B tenders.
Primary Indications
Endocrinology: Treatment of Type 2 Diabetes Mellitus in adults.
Public Health: Ideal for large-scale management of diabetic populations where high-efficacy, low-cost intervention is physically required.
Compliance: Reduces “pill burden” by combining two essential medications into one.
Usage Instructions
Administration: Swallow the tablet physically whole with a glass of water.
Timing: It is physically critical to take this medication with or immediately after the first main meal of the day. This chemically optimizes glucose control and physically reduces the risk of stomach upset.
Hypoglycemia Awareness: Because it contains Glibenclamide, patients should physically carry a source of sugar in case of a chemical drop in blood sugar (Hypoglycemia).
Monitoring: Regular HbA1c and Blood Glucose monitoring is physically required to assess chemical efficacy and prevent long-term complications.
Safety Warning: For Oral Use Only. Lactic Acidosis: Rare but severe physical risk associated with Metformin; monitor renal function chemically. Hypoglycemia Note: Glibenclamide can physically cause significant blood sugar drops if meals are skipped. Contraindication: Do not use in patients with Type 1 Diabetes, severe renal or hepatic impairment, diabetic ketoacidosis, or known hypersensitivity to any of the ingredients.
Global Export & Contract Manufacturing
Healthy Inc is a premier Anti-Diabetic and Public Health Pharmaceutical Exporter in India. As a verified Medicine Supplier in Mumbai, we offer flexible Third Party Manufacturing (Contract Manufacturing) for high-volume diabetic FDCs. Whether you are a National Diabetes Program in the CIS or a B2B Pharma Marketplace partner in Africa or SE Asia, we ensure secure, WHO-GMP compliant delivery.
Commercial Inquiries:
WhatsApp/Call: +91 7710003340
Email: info@healthyinc.co.in
